Weekly Dosing of Malarone ® for Prevention of Malaria
Information source: Walter Reed Army Institute of Research (WRAIR)
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Malaria
Intervention: Atovaquone Proguanil (Drug); Procedure - malaria challenge (Other)
Phase: Phase 2
Status: Recruiting
Sponsored by: US Army Office of the Surgeon General Official(s) and/or principal investigator(s):
Gregory Deye, MD, Principal Investigator, Affiliation: Walter Reed Army Institute of Research (WRAIR)
Overall contact:
Debra Minnick, Phone: 301-319-9332, Email: trials.clinical@amedd.army.mil
Summary
The purpose of this study is to determine whether Malarone ®, which is a drug approved to
prevent malaria when taken daily, will still effectively prevent malaria if taken weekly.
Clinical Details
Official title: Pilot Evaluation of Weekly Dosing of Atovaquone/Proguanil (Malarone ®) for Malaria Chemoprophylaxis
Study design: Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: Blood samples from volunteers will be analyzed for the presence of malaria parasites. The percent of volunteers in each arm protected from malaria will be calculated.
Secondary outcome: Drug levels of atovaquone associated with protection from malaria, blood levels of atovaquone, proguanil and metabolites of these drugs will be measured.
Detailed description:
In this study, two groups of volunteers will be exposed to malaria through the bites of
infected mosquitoes. In one group, volunteers will be randomly assigned to one of 5 arms.
Each of these arms will receive a different dose of Malarone®, a drug known to prevent
malaria when taken daily. Each of these doses will be lower than the maximum approved dose
of this medicine. The other group will not be treated with any drug that could prevent
symptoms or infection.
After exposure, both groups will be monitored for a period of approximately 3 months to see
if they develop symptoms of malaria. Any subjects who do so will be treated with appropriate
medications. Subjects in both groups will have their blood checked regularly during this
period for the presence of malaria parasites. At the completion of the study, results will
be analyzed to determine whether any of the doses of Malarone might effectively prevent
malaria if taken weekly rather than daily.
Eligibility
Minimum age: 18 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- A male or non-pregnant, non-lactating female 18 to 50 years of age (inclusive) at the
time of screening
- Free of clinically significant health problems
- Baseline ECG before entering into the study
- Available to participate for duration of study (approximately 4 months, not including
screening period)
- If the participant is female, not pregnant or lactating and willing to use
contraception to prevent pregnancy
- BMI between 19 and 30
Exclusion Criteria:
- History of malaria or travel to a malarious country within the previous 12 months
- History of participation in a study in which potential exposure to malaria or
vaccination against malaria occurred.
- Planned travel to malarious areas during the study period.
- History of malaria chemoprophylaxis within 60 days prior to time of study entry.
- Chronic use of antibiotics with anti-malarial effects
- Chronic use (defined as more than 14 days)of immunosuppressants or other
immune-modifying drugs within six months of study entry.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, including
human immunodeficiency virus (HIV) infection
- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
functional abnormality, as determined by physical examination, ECG or laboratory
screening tests
- Significant unexplained anemia
- History of sickle cell disease or sickle cell trait
- Seropositive for hepatitis B or hepatitis C
- History of splenectomy
- Pregnant or lactating female, or female who intends to become pregnant during the
study
- Suspected or known current alcohol abuse as defined by the American Psychiatric
Association in DSM IV
- History of a neuropsychiatric disorder (anxiety, depression, psychosis,
schizophrenia)
- Chronic or active illicit and/or intravenous drug use
- History of allergy to atovaquone, proguanil or chloroquine
- History of psoriasis
- Concurrent participation in other research studies
Locations and Contacts
Debra Minnick, Phone: 301-319-9332, Email: trials.clinical@amedd.army.mil
Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States; Recruiting
Debra Minnick, Phone: 301-319-9332, Email: trials.clinical@amedd.army.mil
Robin Nielsen, Phone: 1-866-856-3259, Email: trials.clinical@amedd.army.mil
Additional Information
Starting date: September 2009
Ending date: May 2010
Last updated: September 24, 2009
|
